By sequencing 72,501 individual kidney cells, researchers saw some shared transcriptional patterns in kidney cancers and developing or adult kidneys.
Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
Under a new partnership, Finnish DTC testing company Negen will send its raw genetic test data to BC Platforms to aid in reporting test results to clinicians.
Genomic analysis uncovered genetic, transcriptional, and drug response shifts between different cultures, or "strains," of the same human cancer cell lines.
As part of an NIH SBIR grant, Genomenon is automating the curation of medical literature in its Mastermind variant interpretation software.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
The startup's first test focuses on diagnosing 60 conditions for which treatment is available.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
The platform can now measure RNA and proteins simultaneously at the single-cell level and can multiplex more than 100 proteins per experiment, the company said.
Nonprofit eMQT will use Shivom's decentralized blockchain platform to store and share genomic data of sickle-cell diseases in underserved regions.
With panel sequence data from Ambry's clinical lab and a TNBC research consortium, researchers saw risky hereditary variants in BRCA1/2 and other genes.
As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.
The lawsuit makes broad accusations that companies stole trade secrets related to universal array technology.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
The Suzhou, China-based company is developing medicines and molecular diagnostics based on its gene editing and delivery technologies.
Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.
Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.
In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.
Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.